EN
Sinovac Foundation Donates Poliomyelitis Vaccines to Bangladesh
DHAKA, Bangladesh, May 13, 2026 — Sinovac Foundation has donated 76,616 vials (383,080 doses) of SINOVAC’s Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains (sIPV) to bolster Bangladesh’s polio eradication efforts.
Photo Credit: Press Information Department (PID), Bangladesh.
The official handover ceremony was held at the conference room of the Bangladesh Secretariat in Dhaka. During the ceremony, Li Ning, representing Sinovac Foundation, formally handed over the vaccine donation to Sardar Md. Sakhawat Husain, Minister for Health and Family Welfare of Bangladesh.
Photo Caption: Mr. Sardar Md. Sakhawat Husain, Honorable Minister for Health and Family Welfare of the Government of the People’s Republic of Bangladesh, receives a symbolic token of the donated vaccine during a ceremony held at the Bangladesh Secretariat in Dhaka on May 13, 2026. Photo Credit: Press Information Department (PID), Bangladesh.
Minister Sardar Md. Sakhawat Husain expressed sincere gratitude to Sinovac Foundation for the timely humanitarian support. He commented that the WHO-prequalified sIPV would effectively reinforce Bangladesh's Expanded Programme on Immunization (EPI), improve pediatric vaccination coverage in remote areas, and strengthen the country's national polio prevention capacity.
Li Shaopeng, Cultural Counselor of the Chinese Embassy in Dhaka, stated that this vaccine donation embodies the profound friendship between China and Bangladesh and underscores the two nations' joint commitment to public health security.
Li Ning, representing Sinovac Foundation, emphasized that vaccination is the most effective intervention against poliomyelitis. She noted that Sinovac Foundation was honored to support Bangladesh's national immunization agenda.
The ceremony was also attended by Huang Moucong, Second Secretary of the Chinese Embassy in Dhaka, as well as senior officials from Bangladesh's DGHS, EPI, DGDA and other relevant health authorities.
Moving forward, Sinovac Foundation will continue to assist in optimizing local healthcare systems and strengthen bilateral public health cooperation to advance global immunization outcomes. The Foundation will continue to expand vaccine accessibility and promote sustainable public health development across Bangladesh.
About SINOVAC Foundation
Beijing SINOVAC Foundation (hereinafter referred to as "SINOVAC Foundation") was established by SINOVAC to actively perform its social responsibilities. SINOVAC Foundation focuses on promoting the sustainable development in the biomedical field, provides vigorous support to the scientific and technological innovation in the life health field, and contributes wisdom and power to social harmony and health by funding scientific research innovation projects, promoting academic exchanges and talent cultivation, and timely responding to natural disasters, accidents, publichealth incidents and other emergencies.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines, recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.